Cargando…
Treatment of hereditary angioedema with plasma-derived C1 inhibitor
BACKGROUND: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety...
Autores principales: | Prematta, Michael J, Prematta, Tracy, Craig, Timothy J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621399/ https://www.ncbi.nlm.nih.gov/pubmed/19209279 |
Ejemplares similares
-
Assessing and Treating Work-Related Asthma
por: Stoughton, Tracy, et al.
Publicado: (2008) -
A Pediatric Food Allergy Support Group Can Improve Parent and Physician Communication: Results of a Parent Survey
por: Sharma, Ashika, et al.
Publicado: (2012) -
Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010) -
Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema
por: Frank, Michael M
Publicado: (2010) -
Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor
por: Bork, Konrad
Publicado: (2010)